Cardiac complications of secondary hyperparathyroidism in chronic hemodialysis patients
To evaluate the effects of intact parathormone (iPTH) on left ventricular function using transthoracic echocardiography on chronic hemodialysis (HD) patients with secondary hyperparathyroidism. In HD patients, mortality is high and is frequently due to cardiac complications. Secondary hyperparathyroidism, high levels of phosphate (PO4), and high calcium phosphate product (Ca × PO4) are related to cardiac complications. Materials and methods: We examined 20 patients with normal iPTH levels (Group 1) and 20 patients with high iPTH levels (Group 2). Intact parathormone levels were measured in serum with a Coat-A-Count kit (Diagnostic Products Corporation, Los Angeles, CA, USA) using an immunoradiometric assay. The normal level of iPTH was 0.8-5.2 pmol/L. In patients with end-stage renal disease, iPTH levels should be 1.5 to 3 times higher than the normal range in order to maintain the bone mass; thus, patients with iPTH levels 4 or more times higher than the normal range (PTH >- 20.8 pmol/L) were defined as Group 2 while patients who had normal iPTH levels were defined as Group 1. Results: In both groups, Doppler parameters indicated diastolic dysfunction. However, mitral annular E velocity was lower in Group 2 than in Group 1 (6.1 ± 1.1 cm/s and 7.5 ± 1.6 cm/s, respectively; P = 0.034). It is well known that left ventricular hypertrophy (LVH) increases mortality rates. Left ventricle mass index and relative wall thickness are parameters reflecting LVH, and both were higher in Group 2 (294.4 ± 103.0 g/m² and 53.5 ± 11.7%) when compared with Group 1 (179.2 ± 104.2 g/m² and 41.8 ± 8.9%). These differences were found to be statistically significant (P < 0.001). Conclusion: This study demonstrates that high levels of iPTH contribute to diastolic dysfunction and LVH in hemodialysis patients.
Cardiac complications of secondary hyperparathyroidism in chronic hemodialysis patients
To evaluate the effects of intact parathormone (iPTH) on left ventricular function using transthoracic echocardiography on chronic hemodialysis (HD) patients with secondary hyperparathyroidism. In HD patients, mortality is high and is frequently due to cardiac complications. Secondary hyperparathyroidism, high levels of phosphate (PO4), and high calcium phosphate product (Ca × PO4) are related to cardiac complications. Materials and methods: We examined 20 patients with normal iPTH levels (Group 1) and 20 patients with high iPTH levels (Group 2). Intact parathormone levels were measured in serum with a Coat-A-Count kit (Diagnostic Products Corporation, Los Angeles, CA, USA) using an immunoradiometric assay. The normal level of iPTH was 0.8-5.2 pmol/L. In patients with end-stage renal disease, iPTH levels should be 1.5 to 3 times higher than the normal range in order to maintain the bone mass; thus, patients with iPTH levels 4 or more times higher than the normal range (PTH >- 20.8 pmol/L) were defined as Group 2 while patients who had normal iPTH levels were defined as Group 1. Results: In both groups, Doppler parameters indicated diastolic dysfunction. However, mitral annular E velocity was lower in Group 2 than in Group 1 (6.1 ± 1.1 cm/s and 7.5 ± 1.6 cm/s, respectively; P = 0.034). It is well known that left ventricular hypertrophy (LVH) increases mortality rates. Left ventricle mass index and relative wall thickness are parameters reflecting LVH, and both were higher in Group 2 (294.4 ± 103.0 g/m² and 53.5 ± 11.7%) when compared with Group 1 (179.2 ± 104.2 g/m² and 41.8 ± 8.9%). These differences were found to be statistically significant (P < 0.001). Conclusion: This study demonstrates that high levels of iPTH contribute to diastolic dysfunction and LVH in hemodialysis patients.
___
- Foley RN, Levin A. Cardiovascular disease in chronic renal insuffi ciency. Am J Kidney Dis 2000; 36: S24-S30.
- Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am J Kidney Dis 1998; 32: 853-906.
- Linder A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
- Brenner BM, Rector FC. Brenners and Rector’s Th e Kidney. 6th ed. Philadelphia: W.B. Saunders Company; 2000. p.2121-52.
- Park SH, Shub C, Nobrega TP, Bailey KR, Seward JB. Two-dimensional echocardiographic calculation of left ventricular mass as recommended by the American Society of Echocardiography: correlation with autopsy and M-mode echocardiography. J Am Soc Echocardiogr 1996; 9: 119-28.
- Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy fi ndings. Am J Cardiol 1986; 57: 450-8.
- Randon RB, Rohde LE, Comerlato L, Ribeiro JP, Manfro RC. Th e role of secondary hyperparathyroidism in left ventricular hypertrophy of patients under chronic hemodialysis. Braz J Med Biol Res 2005; 38: 1409-16.
- Bro S, Olgaard K. Eff ects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606-20.
- Smogorzewski M, Zayed M, Zhang YB, Roe J, Massry SG. Parathyroid hormone increases cytosolic calcium concentration in adult rat cardiac myocytes. Am J of Physiology 1993; 264: H1998-2006.
- Amann K, Ritz E, Wiest G, Klaus G, Mall G. A role of parathyroid hormone for the activation of cardiac fi broblasts in uremia. J Am Soc Nephrol 1994; 4: 1814-19.
- McCarty MF, Barnoso-Aranda J, Contreras F. Can moderate elevations of parathyroid hormone acutely increase risk for ischemic cardiac arrhythmias? Med Hypotheses 2009; 72: 581-3.
- Baykan M, Erem C, Erdogan T, Ersöz HO, Gedikli O, Korkmaz L et al. Assessment of left ventricular diastolic function and the Tei index by tissue Doppler imaging in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf) 2007; 66: 483-8.
- Barletta G, De Feo ML, Del Bene R, Lazzeri C, Vecchiarino S, La Villa G et al. Cardiovascular eff ects of parathyroid hormone: a study in healthy subjects and normotensive patients with mild primary hyperparathyroidism. J Clin Endocrinol Metab 2000; 85: 1815-21.
- Ohara N, Hiramatsu K, Shigematsu S, Hayashi Y, Ishihara F, Aizawa T et al. Eff ect of parathyroid hormone on left ventricular diastolic function in patients with primary hyperparathyroidism. Miner Electrolyte Metab 1995; 21: 63-6.
- Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-93.
- Hayashi SY, Rohani M, Lindholm B, Brodin LA, Lind B, Barany P et al. Left ventricular function in patients with chronic kidney disease evaluated by colour tissue Doppler velocity imaging. Nephrol Dial Transplant 2006; 21: 125- 32.
- Park C, Oh Y, Shin Y, Kim C, Kim Y, Kim S et al. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis 1999; 33: 73-81.
- Hara S, Ubara Y, Arizono K, Ikeguchi H, Katori H, Yamada A et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner Electrolyte Metab 1995; 21: 72-6.
- Nanasato M, Goto N, Isobe S, Unno K, Hirayama H, Sato T et al. Restored cardiac conditions and left ventricular function aft er parathyroidectomy in a hemodialysis patient. Parathyroidectomy improves cardiac fatty acid metabolism assessed by 123I-BMIPP. Circ J 2009; 73: 1956-60.